Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 15.

Beer, A., Pischke, S., Behrendt, P., Schlue, J., Drebber, U., Kreipe, H., Wedemeyer, H., Manns, M. and Dienes, H. P. (2014). CHRONIC HEPATITIS E - THE SPECTRUM OF HISTOPATHOLOGY. J. Hepatol., 60 (1). S. S305 - 1. AMSTERDAM: ELSEVIER SCIENCE BV. ISSN 1600-0641

Christgen, M., Harbeck, N., Gluz, O., Raap, M., Christgen, H., Clemens, M., Malter, W., Nuding, B., Aktas, B., Kuemmel, S., Reimer, T., Stefek, A., Krabisch, P., Just, M., Graeser, M., Baehner, R., Wuerstlein, R., Nitz, U., Kates, R. and Kreipe, H. (2020). High likelihood of actionable pDifferential impact of prognostic parameters in hormone receptor-positive lobular early breast cancer in the WSG PlanB trialathogenic variant detection in breast cancer genes in women with very early onset breast cancer, but low rate of additional panel genes. Eur. J. Cancer, 138. S. S1 - 1. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852

Giuz, O., Kreipe, H., Degenhardt, T., Kates, R., Christgen, M., Liedtke, C., Shak, S., Clemens, M., Markmann, S., Uleer, C., Augustin, D., Thomssen, C., Nitz, U. and Harbeck, N. (2011). Prospective Comparison of Risk Assessment Tools in Early Breast Cancer (Recurrence Score, uPA/PAI-1, Central Grade, and Luminal Subtypes): Final Correlation Analysis from the Phase III WSG-Plan B Trial. Cancer Res., 71. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445

Gluz, O., Erber, R., Kates, R., Kreipe, H., Bartels, A., Liedtke, C., Pelz, E., Huober, J., Kuhn, W., Nitz, U., Hartmann, A., Harbeck, N. and Bruenner, N. (2011). Predictive Value of HER2, Topoisomerase-II (Topo-II) and Tissue Inhibitor of Metalloproteinases (TIMP-1) for Efficacy of Taxane-Based Chemotherapy in Intermediate Risk Breast Cancer Results from the EC -Doc Trial. Cancer Res., 71. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445

Gluz, O., Kreipe, H., Christgen, M., Salem, M., Clemens, M., Markmann, S., Liedtke, B., Barinoff, J., Aktas, B., Henschen, S., Luebbe, K., Shak, S., Baehner, R., Liedtke, C., Nitz, U. and Harbeck, N. (2010). Pilot Phase of the Randomized PlanB Trial: Prospective Comparison of Molecular Classification, Oncotype DX (R) and Clinical-Pathological Characteristics in Hormone-Receptor (HR) Positive Primary Breast Cancer. Cancer Res., 70. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445

Gluz, O., Nitz, U., Christgen, M., Kates, R., Clemens, M., Kraemer, S., Nuding, B., Aktas, B., Kuemmel, S., Reimer, T., Lorenz-Salehi, F., Krabisch, P., Just, M., Augustin, D., Liedtke, C., Svedman, C., Shak, S., Wuerstlein, R., Kreipe, H. and Harbeck, N. (2016). Prospective WSG phase III PlanB trial: Clinical outcome at 5 year follow up and impact of 21 Gene Recurrence Score result, central/local-pathological review of grade, ER, PR and Ki67 in HR+/HER2-high risk node-negative and -positive breast cancer. Eur. J. Cancer, 57. S. S6 - 1. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852

Harbeck, N., Nitz, U., Christgen, M., Kuemmel, S., Braun, M., Biehl, C. M., Schumacher, C., Malter, W., Aktas, B., Forstbauer, H., Tio, J., Grischke, E-M., Kolberg-Liedtke, C., de Haas, S., Deurloo, R. J., Kates, R. E., Zu, C. Eulenburg, Wuerstlein, R., Kreipe, H. and Gluz, O. (2021). Predictive impact of biomarkers on pCR and survival after de-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs. trastuzumab+ET in HER2+/HR+ early breast cancer: WSG ADAPT TP trial. Ann. Oncol., 32. S. S1285 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Harbeck, N., Nitz, U., Christgen, M., Kuemmel, S., Braun, M., Schumacher, C., Potenberg, J., Tio, J., Aktas, B., Malter, W., Forstbauer, H., von Schumann, R., Just, M., Jozwiak, K., Hauptmann, M., Kates, R., Graeser, M., Wuerstlein, R. and Kreipe, H. (2020). De-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs trastuzumab plus ET in early HR+/HER2+breast cancer (BC): ADAPT-TP survival results. Ann. Oncol., 31. S. S1146 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Kroeger, N., Alchalby, H., Zabelina, T., Kvasnicka, H. M., Thiele, J., Buesche, G. and Kreipe, H. (2014). RAPID RESOLUTION OF BONE MARROW FIBROSIS ON DAY+100 PREDICTS OUTCOME AFTER ALLOGENEIC SCT IN MYELOFIBROSIS. Bone Marrow Transplant., 49. S. S146 - 2. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365

Nitz, U., Gluz, O., Kreipe, H., Christgen, M., Kates, R. E., Clemenss, M., Kraemer, S., Aktas, B., Kuemmel, S. and Harbeck, N. (2015). Risk assessment by St.Gallen 2013 recommendation and Oncotype DX (R): results from the WSG PlanB trial. Breast, 24. S. S110 - 1. EDINBURGH: CHURCHILL LIVINGSTONE. ISSN 1532-3080

Nitz, U., Gluz, O., Kreipe, H., Christgen, M., Kates, R. E., Clemenss, M., Kraemer, S., Aktas, B., Kuemmel, S. and Harbeck, N. (2015). Risk assessment by St.Gallen 2013 recommendation and Oncotype DX (R): results from the WSG PlanB trial. Breast, 24. S. S110 - 1. EDINBURGH: CHURCHILL LIVINGSTONE. ISSN 1532-3080

Nitz, U. A., Gluz, O., Christgen, M., Grischke, E. -M, Augustin, D., Kuemmel, S., Braun, M., Potenberg, J., Kohls, A., Krauss, K., Stefek, A., Schumacher, C., Forstbauer, H., Reimer, T., Fischer, H., Liedtke, C., Wuerstlein, R., Schumacher, J., Kates, R., Kreipe, H. and Harbeck, N. (2017). De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab +/- weekly paclitaxel. Ann. Oncol., 28 (11). S. 2768 - 2773. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Nitz, U. A. D., Gluz, O., Christgen, M., Grischke, E. -M., Augustin, D., Kuemmel, S., Braun, M., Potenberg, J., Kohls, A., Krauss, K., Stefek, A., Schumacher, C., Forstbauer, H., Reimer, T., Fischer, H., Liedtke, C., Wuerstlein, R., Schumacher, J., Kates, R., Kreipe, H. and Harbeck, N. (2022). De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab +/- weekly paclitaxel (vol 28, pg 2768, 2017). Ann. Oncol., 33 (3). S. 355 - 356. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Nitz, Ulrike, Gluz, Oleg, Clemens, Michael, Malter, Wolfram, Reimer, Toralf, Nuding, Benno, Aktas, Bahriye, Stefek, Andrea, Pollmanns, Anke, Lorenz-Salehi, Fatemeh, Uleer, Christoph, Krabisch, Petra, Kuemmel, Sherko, Liedtke, Cornelia, Shak, Steven, Wuerstlein, Rachel, Christgen, Matthias, Kates, Ronald E., Kreipe, Hans H., Harbeck, Nadia, Ackermann, S., Aktas, B., Augustin, D., Baake, G., Baumann, K., Berger, R., Bettscheider, J., Bischoff, J., Clemens, M., Deryal, M., Dubbers, H., Duchting, D., Dunnebacke, J., Fett, W., Fietz, T., Fischer, H., Forner, M., Forstbauer, H., Freese, K., Geberth, M., Glados, M., Gnauert, K., Goette, O., Gohring, U., Goppinger, A., Grafe, A., Hackenberg, R., Hackmann, J., Hellriegel, M., Heyl, V., Hoestermann, C., Hoffmann, G., Hofmann, M., Hucke, J., Jackisch, C., Jungberg, P., Just, M., Kahl, C., Klare, P., Kogel, M., Kohls, A., Amrawy, B. Konigs-El, Konnecke, P., Krabisch, P., Kraudelt, S., Kremers, S., Kummel, S., Kurbacher, C., Kusche, J., Liedtke, B., Liedtke, C., Link, H., Lorenz, R., Salehi, F. Lorenz, Lubbe, K., Malter, W., Melekian, B., Mobus, V., Montenarh, M., Mueller, V., Mundhenke, C., Niederle, N., Nitz, U., Noesselt, T., Oberhoff, C., Paas, L., Paepke, S., Pollmanns, A., Reichert, D., Reimer, T., Romann, D., Ruhland, T., Runde, V., Salem, M., Schlosser, A., Schneider, A., Schrader, I., Schulz, H., Schumacher, C., Schwickerath, J., Soling, U., Stauder, H., Stefek, A., Steinmetz, T., Stickeler, E., Terhaag, J., Thomssen, C., Tome, O., Uleer, C., Warm, M., Wachsmann, G., Wacker, J., Wiebringhaus, H., Wiest, W., Wolfgarten, M., Nitz, U., Christgen, H., Kreipe, H., Buehne, C., Gluz, O., Hansen, K., Hofmann, D., Kates, R., Mangold, M., Mathissen, M., Raeth, P., Renner, I., Reiser, I., Schumacher, J., Staedele, M. and Walter-Kirst, R. (2019). West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer. J. Clin. Oncol., 37 (10). S. 799 - 811. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Wuerstlein, R., Gluz, O., Kreipe, H., Kates, R., Degenhardt, T., Liedtke, C., Shak, S., Nitz, U. and Harbeck, N. (2011). Prospective comparison of Recurrence Score, uPA/PAI-1, central grade and molecular subtyping in early breast cancer: first results from the WSG-Plan B trial (interim analysis). Eur. J. Cancer, 47. S. S33 - 2. OXFORD: ELSEVIER SCI LTD. ISSN 0959-8049

This list was generated on Fri Mar 29 12:09:15 2024 CET.